A double-blind, placebo-controlled, three-arm, randomised, multi-centre Gynaecologic Cancer InterGroup trial of cediranib (AZD2171), in combination with platinum-based chemotherapy and as a single agent maintenance therapy, in women with ovarian cancer relapsing more than 6 months following completion of first line platinum-based treatment

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data

Contact Back to top ↑

Please note:
  1. The UKCTG information is designed to inform you of existing trials. If you wish to join a specific trial, you must discuss this with your own doctor who may decide to get in touch with the contact listed.
  2. Please note: Trial data is sourced from multiple external providers and as such UKCTG is not responsible for, and cannot guarantee, the accuracy of data, including Location information. Please contact us if you have any query regarding the quality of trial records.